BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party - Quiz - MDSpire

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

  • By

  • Raffaella Greco

  • Riccardo Saccardi

  • Marta Ponzano

  • Manuela Badoglio

  • Grzegorz Helbig

  • Marek Smilowski

  • Alice Mariottini

  • Joachim Burman

  • Kristina Carlson

  • Majid Kazmi

  • Paolo A. Muraro

  • Ian Gabriel

  • Barbara Withers

  • Jennifer Massey

  • Riccardo Varaldo

  • Matilde Inglese

  • Jaime Sanz

  • Sara Gil-Perotin

  • Basil Sharrack

  • Elisa Roldan

  • Chiara Nozzoli

  • Alessio Signori

  • Maria Pia Sormani

  • Tobias Alexander

  • John A. Snowden

  • September 29, 2025

  • 0 min

Share

Original Source(s)

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

  • by Raffaella Greco, Riccardo Saccardi, Marta Ponzano, Manuela Badoglio, Grzegorz Helbig, Marek Smilowski, Alice Mariottini, Joachim Burman, Kristina Carlson, Majid Kazmi, Paolo A. Muraro, Ian Gabriel, Barbara Withers, Jennifer Massey, Riccardo Varaldo, Matilde Inglese, Jaime Sanz, Sara Gil-Perotin, Basil Sharrack, Elisa Roldan, Chiara Nozzoli, Alessio Signori, Maria Pia Sormani, Tobias Alexander, John A. Snowden

  • September 29, 2025

Related Content

CAR-T cell therapy embarks on autoimmune disease

Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis

BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis